

Test Report: EN 1276 2009 Chemical disinfectants and antiseptics – Quantitative suspension test for the evaluation of bactericidal activity of chemical disinfectants and antiseptics used in food, industrial, domestic and institutional areas — Test method and requirements (phase 2, step 1)

Test Laboratory

BluTest Laboratories Ltd

Robertson Incubator (Level 4)

Robertson Building 56 Dumbarton Road

Glasgow UK - G11 6NU

Identification of sample

Name of the product

Batch number

Client

CreBiSol X10

28.5.14

CREATIVE BIOCIDAL SOLUTIONS LIMITED

First Floor, Block C, Balbriggan Business Campus,

Balbriggan, CO Dublin

BT-HIP-02A(1)

30 May 2014

Cool, well ventilated area. Keep container tightly closed

DDQ50

Project Code
Date of Delivery
Storage conditions
Active substances

Test Method and its validation

Method

Neutralizer

Chemical-neutralization

Lecithin 11.7g/l, Polysorbate 80 100g/l, sodium thiosulphate 5.0g/l, sodium dodecyl sulphate 10.0g/l, sodium chloride 8.5g/l, tryptone 1.0g/l sterilized by

autoclave

Experimental Conditions

Period of analysis

Product diluent used

Product test concentrations

Appearance product dilutions

26-27 June 2014

Sterile, synthetic hard water

1.0 % V/V; 2.0 % V/V; 5.0 % V/V: 10.0 % V/V

Test mixture becomes cloudy at 10%, 5%, 2%, 1% and

Control C

 $t = 30 s \pm 10 s$

 $20^{\circ}C \pm 1^{\circ}C$

3.0g/I bovine serum albumin

Stable

 $37 \,^{\circ}\text{C} \pm 1 \,^{\circ}\text{C}$

MRSA UK15

Contact time

Test temperature

Interfering substance

Stability of mixture

Temperature of incubation

Identification of strains

Page 1 of 3



EN 1276 Results for the efficacy of CreBiSol X10 from Creative Biocidal Solutions Ltd under DIRTY CONDITIONS

Test organisms		Validat	Validation test		Bacterial test		Test p	rocedure at con	Test procedure at concentration % (V/V)	۸)
	Racterial	Exnerimental	Neutralizer	Dilution-	suspension (N)		1.00%	2.00%	2.00%	10.00%
	Suspension (Nv)	conditions (A)	toxicity Control or	ne						
			filtration control	control or						
			(B)	filtration test						
				9						,
MRSA UK15	Vc: 49 ; 52	Vc: 40; 48	Vc: 44 ; 48	Vc: 59 ; 64	10 ⁻⁸ ; 215 ; 221	z	32 ; 37	2 ; 4	0 :	1 ;
Neat		W. C.			10 ⁻⁹ : 17 ; 27	Na	3.45E+02	<1.40E+02	<1.40E+02	<1.40E+02
					N: 2.18E+10	~	<10(8)	>10(8)	>10(8)	>10(8)
ATCC 15442	Nv: 5.05E+02	A: 4.40E+01	B: 4.60E+01	C: 6.15E+01						
Validation	$30 \le Nv_0 \le 160$?	A≥0.5 x Nv ₀ ?	B≥0.5×Nv ₀ ?	C≥ 0.5 x Nv ₀ ?	9.17≤ log N ₀ ≤9.70?			Tost is valid	Pilen	
	yes	yes	yes	yes	yes					
MRSA UK15	Vc: 49 ; 52	Vc: 40 ; 48	Vc: 44 ; 48	Vc: 59 ; 64	10 ⁻⁸ ; 215 ; 221	1-	4 ; 6	0 : 0	0 ; 1	0 : 0
10E-1 product					10°9; 17; 27	Na	<1.40E+02	<1.40E+02	<1.40E+02	<1.40E+02
•					N: 2.18E+10	~				
ATCC 15442	Nv: 5.05E+02	A: 4.40E+01	B: 4.60E+01	C: 6.15E+01						
Validation	30 ≤ Nv ₀ ≤ 160 ?	A≥0.5 x Nv ₀ ?	B≥0.5 x Nv ₀ ?	C≥0.5 x Nv ₀ ?	9.17≤ log N ₀ ≤9.70?			Test is valid	halid	
	yes	yes	yes	yes	yes				5	
MRSA UK15	Vc: 49 ; 52	Vc: 40 ; 48	Vc: 44 ; 48	Vc: 59 ; 64	10 ⁻⁸ ; 215 ; 221	7-	1;3	0 : 0	0 : 0	0 : 0
10E-2 product					10-9: 17; 27	Na	<1.40E+02	<1.40E+02	<1.40E+02	<1.40E+02
					N: 2.18E+10	~				
ATCC 15442	Nv: 5.05E+02	A: 4.40E+01	B: 4.60E+01	C: 6.15E+01						
Validation	$30 \le Nv_0 \le 160$?	A≥0.5 x Nv ₀ ?	B≥0.5 x Nv ₀ ?	C≥0.5 x Nv ₀ ?	9.17≤ log N ₀ ≤9.70?			Test is valid	valid	
	yes	yes	yes	yes	yes					

See comments below

Vc = viable count

N = number of cfu/ml of the bacterial test suspension

Vv = number of cfu/ml in the bacterial suspension

= reduction in viability

Va = number of cfu/ml in the test mixture

= number of cfu/ml of the experimental conditions validation

= number of cfu/ml of the neutralizer toxicity validation or of the filtration validation

= the number of cfu/ml of the dilution-neutralization validation or the membrane filtration test validation

COMMENTS

Test carried out using ~1.5-5.0 x 10.10 cfu/ml as specified by the client. Additional dilutions to be carried out for test plates (10.1 and 10-2). Make ~50mls of N (at 1.5-5.0 x 109 cfu/ml). Read 10-1 on the spec. to check the range. Centrifuge at 2000g

SOP 11000 SOP 8000 EN1276 REPORT TEMPLATE V06 Effective Date: 16 June 2014

BT-HIP-02A(1)
Robertson Incubator, Level 4, Robertson Building, 56 Dumbarton Road, Glasgow, G11 6NU
Email: info@blutest.com Website: www.blutest.com

Company Registration Number: SC364409 VAT Registration Number: GB 979 1131 96



Conclusion

According to a modified EN 1276 2009 procedure, CreBiSol X10 POSESSES BACTERICIDAL activity of > 8.0 log₁₀ reduction at a concentration of 2.0 % V/V as tested after 30 SECONDS at 20°C under DIRTY conditions (3.0 g/l bovine serum albumin) against Meticillin resistant Staphylococcus aureus strain UK 15.

Signed

Dr Chris Woodall, Director BluTest Laboratories Ltd

Glasgow, UK,

Date: 30 April 2015

Expanded Uncertainty of Measurement U = ± 0.49 logs

DISCLAIMER

The results in this test report only pertain to the sample supplied.

BluTest (BT) has performed the testing detailed in this report using reasonable skill and care and has used reasonable endeavours to carry out the testing in accordance with a modified EN 1276 protocol. All forecasts, recommendations and results contained in this report are submitted in good faith. However, other than as expressly set out in this report, no warranty is given (i) in relation to the testing or the use(s) to which any results or deliverables produced in the course of the testing are or may be put by the Client or their fitness or suitability for any particular purpose or under any special conditions notwithstanding that any such purpose or conditions may have been made known to BT or (ii) that the intended results or deliverables from the testing can be achieved or (iii) that the Client can freely make use of the results or the deliverables without infringing any third party intellectual property rights and the Client will be deemed to have satisfied itself in this regard. BT shall have no liability (which is hereby excluded to the fullest extent permissible by law) in respect of any loss, liability or damage, including without limitation any indirect and/or consequential loss such as loss of profit or loss of business, market or goodwill, that the Client may suffer directly or indirectly as a result of or in connection with: (i) the performance of the testing; (ii) the use of any materials, samples or other information provided by the Client for use in the testing; and (iii) the Client's reliance upon or use of any results or deliverables provided as part of the testing.